Apex Immune Therapeutics Company Overview

MEDIA BACKGROUNDE R Contact: Capwell Communications , media@capwellcomm.com EMBARGOED UNTIL 11 A . M . ET WEDNESDAY, SEPT. 9, 2026. Company F acts • Founded: 2016 • Headquarters: South San Francisco, C A • Employees: Nine , all full - time • Focus: Novel immunotherapies for patients who do not respond to existing immune checkpoint inhibitors Capital R aised • Total to date: $32.05 million o $21.3 million Series A, closed March 2025, led by PharmaEssentia Corporation, with DCI Partners, Taya Venture Capital, KDI Marketing, Huahai US, Hercules BioVenture LP, and TTM 2025 LLC. Judy Swanson invested through TTM 2025 LLC. Her late husband, Robert A. Swanson, co - founded Genentech. o $399,618 NIH SBIR Phase I grant, awarded 2023 o $6 million Pre - A preferred equity, announced March 2021 o $4.35 million prior to Pre - A (Seed round) • Series B is open, with most Series A investors already committed Pipeline • AI - 306, lead program . First - in - class monoclonal antibody that blocks both the enzymatic and non - enzymatic activity of PLA2G2D . IND - enabling development. Cell line development underway, GLP toxicology scheduled to begin late 2026, IND filing targeted for Q2 2027. • MEBA platform, macrophage - engaging bispecific antibodies . S even active programs . AI - 328 is at the cell line development stage; IND filing planned for Q3 2027. • Target discovery platform . Bioinformatics across thousands of RNA - seq transcriptomes spanning more than 20 tumor types, built on a proprietary T - cell gene expression signature. More than 30 novel targets identified. • Patents : Six filed across multiple jurisdictions , including three PLA2G2D patents : 1) Methods and compositions for treating cancer or viral infection with a PLA2G2D antagonist, 2) Anti - PLA2G2D constructs and use thereof, 3) Combination therapy comprising anti - PLA2G2D antibodies and uses thereof. Leadership • Li - Fen Lee, PhD, Founder and Chief Executive Officer. Previously AbbVie, NGM, Pfizer, and the Stanford University School of Medicine faculty. Nature senior and co - corresponding author. • James O’Mara, consulting Chief Business Officer. Previously Ironwood Pharmaceuticals, Neurogastrx, MPM Capital.